Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
,
Abstract
Introduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer.
Patient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with Carboplatin (AUC= 6) and Paclitaxel (175 mg/m3) every 4 weeks for 6 cycles, or, until disease progression or severe toxicity.
Result: The ORR was 54% (16 out of 30), CR in 4 and PR in 12. The median progression free survival was 8.2 months. The 6 months overall survival was seen in 80% of trhe patients. The toxicity was generally tolerable.
Conclusion: The combination of Carboplatin plus Paclitaxel was well tolerated in this trial. This regimen demonstrated feasible success in curing advanced endometrial cancer compared to other combination therapies used before (in terms of RR and toxicity).
Jemal A, Murray T, Samuels A, et al. Cancer Statistics CA Cancer. J Clin Oncol, 2000; 53:5-26.
Thigpen JT, Brady MF, Homesley HD, et al. Phase III Trial of Doxorubicin with or without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J clin Oncol, 2004; 22:3902-8.
Fleming GF, Brunetto VL, Cella D, et al. Phase III Trial of Doxorubicin plus Cisplatin with or without Paclitaxel plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J clin Oncol, 2004; 22: 2159-66.
Ozols RF, Bundy BN, Greer BF, et al. Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J clin Oncol, 2003; 21:3194-200.
Greven KM, Winter K, Underhill K, et al. Radiation Therapy Oncology Group. Preliminary Analysis of RTOG 9708: Adjuvant Postoperative Radiotherapy Combined with Cisplatin/Paclitaxel Chemotherapy after Surgery for Patients with High-risk Endometrial Cancer. Int J Radiat Oncol Biol Phys, 2004; 1 59 (1):168-73.
Lincoln S, Blessing JA, Lee RB, e al. Activity of Paclitaxel as Second-line Chemotherapy in Endometrial Carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol, 2003; 88: 277-81.
Marrow PC, Bundy BN, Homesley HD, et al. Doxorubicin as an Adjuvant Following Surgery and Radiation Therapy in Patients with High-risk Endometrial Carcinoma, Stage I and Occult Stage II: A Gynecologic Oncology Group Study. Gynecol Oncol, 1990; 36: 166-71.
Duska LR, Berkowitz R, Matulonis U, et al. A Pilot Trial of TAC Chemotherapy with Filgastrin Support Followed by Radiotherapy in Patients with High-risk Endometrial Cancer. Gynecol Oncol, 2005; 96(1): 198-203.
Mundt A, McBride R, Rotmensch J, et al. Significant Pelvic Recurrence in High-risk Pathologic Stage I-IV Endometrial Carcinoma Patients after Adjuvant Chemotherapy Alone: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys, 2001; 50: 1145-53.
Randall ME, Filiaci VL, Muss H, et al. Randomized Phase III Trial of Whole-Abdominal Irradiation versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. JCO 2006; 24: 36-44.
Katsumata N, Noda K, Nozawa S, et al. Phase II Trial of Docetaxel in Advanced or Metastatic Endometrial Cancer: A Japanese Cooperative Study. Br J Cancer. 2005; 93(9): 999- 1004.
Scudder SA, Liu RY, Wilczynski SP, et al. Southwest Oncology Group. Paclitaxel and Carboplatin with Amifostine in Advanced, Recurrent, or Refractory Endometrial Adenocarcinoma: A Phase II Study of the Southwest Oncology Group.
| Files | ||
| Issue | Vol 3, No 3 (2009) | |
| Section | Articles | |
| Keywords | ||
| Endometrial cancer Carboplatin Paclitaxel | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
